New insights into the impact of impaired epigenetic machinery on liver cancer malignant phenotype
Rebeca P. Marijuan,Jose J. G. Marin
DOI: https://doi.org/10.21037/tcr-24-751
2024-10-01
Translational Cancer Research
Abstract:Rebeca P. Marijuan 1 , Jose J. G. Marin 1,2,3 1 Experimental Hepatology and Drug Targeting (HEVEPHARM), Department of Physiology and Pharmacology, University of Salamanca, Salamanca, Spain; 2 Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; 3 Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Institute of Health, Madrid, Spain Comment on: Zhang X, Su T, Wu Y, et al . N6-Methyladenosine Reader YTHDF1 Promotes Stemness and Therapeutic Resistance in Hepatocellular Carcinoma by Enhancing NOTCH1 Expression. Cancer Res 2024;84:827-40. Keywords: Chemoresistance; hepatocellular carcinoma (HCC); N 6 -methyladenosine (m 6 A); NOTCH1; YTHDF1 Submitted May 06, 2024. Accepted for publication Sep 12, 2024. Published online Sep 27, 2024. doi: 10.21037/tcr-24-751 Hepatocellular carcinoma (HCC) is the most frequent liver malignancy, representing up to 85–90% of all primary hepatic cancers. Its progression and aggressiveness mainly rely on the existence of liver cancer stem cells (LCSCs), which can self-renew and are responsible for the marked inter-individual, inter-tumors in a single patient, and even intra-tumor cellular heterogeneity seen in HCC. This feature contributes to the recurrence often seen in these patients, even after an initial satisfactory response to systemic treatments, which constitutes a clinically serious problem and positions HCC as the third leading cause of cancer-associated death worldwide. The existence of different subpopulations of LCSCs makes the problem more complex. They can be characterized by specific surface markers, such as EpCAM, LGR5, CD133, CD44, and CD24, or using advanced techniques like single-cell RNA sequencing (1,2). Furthermore, molecular studies can also identify characteristic genetic alterations and modifications in specific signaling pathways of cancer cells that contribute to their aggressive behavior. One primary reason for HCC-associated high mortality (less than 20% survival rate 5 years after diagnosis) is its marked resistance to available chemotherapy, including those based on modern tyrosine kinase inhibitors (TKI), such as sorafenib and lenvatinib. However, even in the best cases, this targeted therapy results in only a moderate improvement in the typically poor outcomes of HCC patients (3). This lack of response is due in part to alterations in signaling pathways, for example, NOTCH1 and Wnt/β-catenin pathways that are crucial for preserving stemness characteristics that are involved in malignant traits of HCC cells, including chemoresistance. Interestingly, the stemness features can also be regulated by epigenetic mechanisms, some of which have been previously related to the development of liver tumors (4). The recently published study by Zhang et al. (5) further investigated this clinically relevant issue. The orchestrated intervention of the epigenetic machinery, involving writer, reader, and eraser elements broadens the phenotypic traits beyond those merely based on information contained in the genome. Epigenetic processes, leading to DNA/RNA methylation, nucleosome remodeling, and histone modification, among others, are involved in the control of many different functions in health and disease. More precisely, they play a crucial role in cancer, in general, and HCC in particular (6,7). Epigenetic mechanisms are central to the complex interplay between genetic and environmental drivers of HCC, as they facilitate the integration and amplification of the effects mediated by these factors. HCC progression is often driven by a combination of environmental events, which include recurring inflammatory infections due to hepatitis viruses (mainly B and C), alcohol consumption, and diabetes. Additionally, genetic mutations, such as those affecting tumor suppressor genes and oncogenes also play an important role in HCC development and progression (8). These environmental factors can account for epigenetic changes being induced, such as altered DNA methylation patterns or histone modifications, which in turn affect gene expression and eventually tumor behavior. For instance, the exposure to aflatoxins can affect the DNA methylation patterns affecting the expression/function of the tumor suppressor gene TP53 and the growth-regulator H19 (9). Furthermore, chronic hepatitis B or C infections can result in aberrant methylation of genes, such as N 6 -methyladenosine (m 6 A) modification of PTEN mRNA (10). Moreover, the advancement in our understanding of epigenetic mechanisms and their essential players has settled the basis for developing novel strategies for sensitizing HCC cells to pharmacological treatments (11). Thus, a novel field of interest in the search for druggable target -Abstract Truncated-
oncology